vs
LXP Industrial Trust（LXP）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是LXP Industrial Trust的1.5倍（$127.1M vs $86.7M），再鼎医药同比增速更快（17.1% vs -14.0%），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.3%）
LXP工业信托是一家公开上市的房地产投资信托，专注于持有、运营和投资美国核心市场的优质工业地产，主要涵盖配送中心、物流设施及轻型工业物业，服务电商、第三方物流、先进制造等领域租户，为投资者创造长期稳定收益。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
LXP vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$86.7M
营收增速更快
ZLAB
高出31.1%
-14.0%
两年增速更快
ZLAB
近两年复合增速
0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.7M | $127.1M |
| 净利润 | $28.8M | — |
| 毛利率 | 81.5% | 51.0% |
| 营业利润率 | 34.6% | -54.6% |
| 净利率 | 33.2% | — |
| 营收同比 | -14.0% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LXPZLAB
| Q4 25 | $86.7M | $127.1M | ||
| Q3 25 | $86.9M | $115.4M | ||
| Q2 25 | $87.7M | $109.1M | ||
| Q1 25 | $88.9M | $105.7M | ||
| Q4 24 | $100.9M | $108.5M | ||
| Q3 24 | $85.6M | $101.8M | ||
| Q2 24 | $85.8M | $100.1M | ||
| Q1 24 | $86.3M | $87.1M |
净利润LXPZLAB
| Q4 25 | $28.8M | — | ||
| Q3 25 | $36.3M | $-36.0M | ||
| Q2 25 | $29.1M | $-40.7M | ||
| Q1 25 | $19.0M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.3M | $-41.7M | ||
| Q2 24 | $5.4M | $-80.3M | ||
| Q1 24 | $-269.0K | $-53.5M |
毛利率LXPZLAB
| Q4 25 | 81.5% | 51.0% | ||
| Q3 25 | 82.3% | 59.5% | ||
| Q2 25 | 81.9% | 60.6% | ||
| Q1 25 | 80.7% | 63.6% | ||
| Q4 24 | 85.3% | 61.5% | ||
| Q3 24 | 82.5% | 64.1% | ||
| Q2 24 | 82.0% | 64.9% | ||
| Q1 24 | 82.4% | 61.4% |
营业利润率LXPZLAB
| Q4 25 | 34.6% | -54.6% | ||
| Q3 25 | 50.4% | -42.3% | ||
| Q2 25 | 33.7% | -50.3% | ||
| Q1 25 | 21.8% | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | 7.9% | -66.6% | ||
| Q2 24 | 6.9% | -76.0% | ||
| Q1 24 | 1.0% | -80.7% |
净利率LXPZLAB
| Q4 25 | 33.2% | — | ||
| Q3 25 | 41.7% | -31.2% | ||
| Q2 25 | 33.2% | -37.3% | ||
| Q1 25 | 21.4% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.4% | -40.9% | ||
| Q2 24 | 6.3% | -80.2% | ||
| Q1 24 | -0.3% | -61.4% |
每股收益（稀释后）LXPZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $0.12 | $-0.03 | ||
| Q2 25 | $0.09 | $-0.04 | ||
| Q1 25 | $0.06 | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $0.02 | $-0.04 | ||
| Q2 24 | $0.01 | $-0.08 | ||
| Q1 24 | $-0.01 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $170.4M | $689.6M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $2.0B | $715.5M |
| 总资产 | $3.5B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.66× | — |
8季度趋势，按日历期对齐
现金及短期投资LXPZLAB
| Q4 25 | $170.4M | $689.6M | ||
| Q3 25 | $229.7M | $717.2M | ||
| Q2 25 | $71.0M | $732.2M | ||
| Q1 25 | $70.9M | $757.3M | ||
| Q4 24 | $101.8M | $779.7M | ||
| Q3 24 | $55.0M | $616.1M | ||
| Q2 24 | $48.7M | $630.0M | ||
| Q1 24 | $293.8M | $650.8M |
总债务LXPZLAB
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LXPZLAB
| Q4 25 | $2.0B | $715.5M | ||
| Q3 25 | $2.1B | $759.9M | ||
| Q2 25 | $2.1B | $791.7M | ||
| Q1 25 | $2.1B | $810.8M | ||
| Q4 24 | $2.1B | $840.9M | ||
| Q3 24 | $2.1B | $667.7M | ||
| Q2 24 | $2.1B | $704.2M | ||
| Q1 24 | $2.2B | $762.2M |
总资产LXPZLAB
| Q4 25 | $3.5B | $1.2B | ||
| Q3 25 | $3.7B | $1.2B | ||
| Q2 25 | $3.7B | $1.2B | ||
| Q1 25 | $3.8B | $1.2B | ||
| Q4 24 | $3.8B | $1.2B | ||
| Q3 24 | $3.9B | $985.3M | ||
| Q2 24 | $3.9B | $987.4M | ||
| Q1 24 | $4.2B | $988.4M |
负债/权益比LXPZLAB
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $188.7M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 6.56× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流LXPZLAB
| Q4 25 | $188.7M | $-26.0M | ||
| Q3 25 | $63.5M | $-32.0M | ||
| Q2 25 | $44.3M | $-31.0M | ||
| Q1 25 | $39.0M | $-61.7M | ||
| Q4 24 | $211.2M | $-55.8M | ||
| Q3 24 | $64.6M | $-26.8M | ||
| Q2 24 | $38.5M | $-42.2M | ||
| Q1 24 | $38.9M | $-90.1M |
自由现金流LXPZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率LXPZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度LXPZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率LXPZLAB
| Q4 25 | 6.56× | — | ||
| Q3 25 | 1.75× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 2.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.18× | — | ||
| Q2 24 | 7.09× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LXP
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
